Baczyk M - Search Results

1

Fractionated dosage of radioiodine for the ablation of differentiated thyroid carcinoma.

Czepczyński R, Ziemnicka K, Baczyk M, Oleksa R, Ruchała M, Sowiński J. Czepczyński R, et al. Among authors: baczyk m. Thyroid. 2005 Nov;15(11):1261-5. doi: 10.1089/thy.2005.15.1261. Thyroid. 2005. PMID: 16356090

2

Therapy of large multinodular goitre using repeated doses of radioiodine.

Baczyk M, Pisarek M, Czepczyński R, Ziemnicka K, Gryczyńska M, Pietz L, Sowiński J. Baczyk M, et al. Nucl Med Commun. 2009 Mar;30(3):226-31. doi: 10.1097/MNM.0b013e328320eb03. Nucl Med Commun. 2009. PMID: 19262285 Clinical Trial.

3

Peptide receptor radionuclide therapy of differentiated thyroid cancer: efficacy and toxicity.

Czepczyński R, Matysiak-Grześ M, Gryczyńska M, Bączyk M, Wyszomirska A, Stajgis M, Ruchała M. Czepczyński R, et al. Among authors: baczyk m. Arch Immunol Ther Exp (Warsz). 2015 Apr;63(2):147-54. doi: 10.1007/s00005-014-0318-6. Epub 2014 Nov 18. Arch Immunol Ther Exp (Warsz). 2015. PMID: 25403743 Free PMC article. Clinical Trial.

4

Fractionated dosage of radioiodine for the ablation of low-risk differentiated thyroid cancer has no impact on survival.

Woliński K, Czepczyński R, Stangierski A, Trojanowski M, Rewaj-Łosyk M, Ziemnicka K, Bączyk M, Dyzmann-Sroka A, Ruchała M. Woliński K, et al. Among authors: baczyk m. Endokrynol Pol. 2018;69(3):230-234. doi: 10.5603/EP.a2018.0017. Epub 2018 Mar 5. Endokrynol Pol. 2018. PMID: 29504625 Free article.

5

Predictive factors determining incomplete response to radioiodine therapy in patients with differentiated thyroid cancer.

Szczepanek-Parulska E, Wojewoda-Korbelak M, Borowczyk M, Kaluzna M, Brominska B, Ziemnicka K, Czepczynski R, Baczyk M, Ruchala M. Szczepanek-Parulska E, et al. Among authors: baczyk m. Q J Nucl Med Mol Imaging. 2020 Mar;64(1):115-123. doi: 10.23736/S1824-4785.18.03026-1. Epub 2018 Sep 13. Q J Nucl Med Mol Imaging. 2020. PMID: 30221905

6

[Autoimmunization and multinodular large toxic goiter therapy using repeated doses of 131I].

Pisarek M, Baczyk M, Gryczyńska M, Pietz L, Ziemnicka K, Sowiński J. Pisarek M, et al. Among authors: baczyk m. Pol Arch Med Wewn. 2006 Jun;115(6):545-50. Pol Arch Med Wewn. 2006. PMID: 17263226 Polish.

7

89Sr versus 153Sm-EDTMP: comparison of treatment efficacy of painful bone metastases in prostate and breast carcinoma.

Baczyk M, Czepczyński R, Milecki P, Pisarek M, Oleksa R, Sowiński J. Baczyk M, et al. Nucl Med Commun. 2007 Apr;28(4):245-50. doi: 10.1097/MNM.0b013e32805b72a0. Nucl Med Commun. 2007. PMID: 17325585 Clinical Trial.

8

Changes in thyroid morphology and function in children in western Poland as a result of intensified iodine prophylaxis.

Baczyk M, Ruchała M, Pisarek M, Pietz L, Junik R, Sowiński J, Gembicki M. Baczyk M, et al. J Pediatr Endocrinol Metab. 2007 Apr;20(4):511-5. doi: 10.1515/jpem.2007.20.4.511. J Pediatr Endocrinol Metab. 2007. PMID: 17550215 Clinical Trial.

9

[Salivary gland damage after 131I therapy in patients with differentiated thyroid cancer. Preliminary report].

Macioszek A, Baczyk M, Kopeć T, Sowiński J. Macioszek A, et al. Among authors: baczyk m. Endokrynol Pol. 2008 Sep-Oct;59(5):403-10. Endokrynol Pol. 2008. PMID: 18979451 Polish.

10

Iodine prophylaxis intensification. Influence on radioiodine uptake and activity of 131I used in the treatment of hyperthyroid patients with Graves' disease.

Baczyk M, Junik R, Ziemnicka K, Sowiński J. Baczyk M, et al. Nuklearmedizin. 2005;44(5):197-9. Nuklearmedizin. 2005. PMID: 16395495

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

61 results

Search Page

Filters